MARKET

HCM

HCM

Hutchmed (China) Limited
NASDAQ
18.25
+1.31
+7.73%
Closed 16:00 04/23 EDT
OPEN
17.64
PREV CLOSE
16.94
HIGH
18.46
LOW
17.64
VOLUME
121.70K
TURNOVER
0
52 WEEK HIGH
20.73
52 WEEK LOW
10.68
MARKET CAP
3.18B
P/E (TTM)
31.48
1D
5D
1M
3M
1Y
5Y
HUTCHMED Announces Key Managerial LTIP Vesting
TipRanks · 2d ago
Weekly Report: what happened at HCM last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at HCM last week (0408-0412)?
Weekly Report · 04/15 09:27
Weekly Report: what happened at HCM last week (0401-0405)?
Weekly Report · 04/08 09:29
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
ProfoundBio, A Seattle-Suzhou ADC Biotech, will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. China Medical System in-licensed povorcitinib, an oral JAK1 inhibitor, for autoimmune and inflammatory dermatologic diseases. Shanghai's Visen Pharma announced plans to stage an IPO on the Hong Kong Exchange.
Seeking Alpha · 04/07 10:30
HUTCHMED to Unveil New Cancer Drug Data at AACR 2024
TipRanks · 04/05 11:00
HUTCHMED Says Initial Preclinical Data For HMPL-506 Novel, Highly Potent And Differentiated Menin-MLL Inhibitor For The Treatment Of Certain Types Of Acute Leukemia At AACR Congress 2024
Initial preclinical data will be presented for HMPL-506, a menin-MLL inhibitor for the treatment of certain types of acute leukemia. The drug shows stronger inhibitory potency than five other menin inhibitors in clinical development. A Phase I study is planned for the second half of 2024.
Benzinga · 04/05 09:18
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
New and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research Annual Meeting 2024. The meeting will take place on April 5-10, 2024 in San Diego, California. Hutchmed.com.
Barchart · 04/05 03:30
More
About HCM
HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.

Webull offers HUTCHMED (China) Ltd (ADR) stock information, including NASDAQ: HCM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HCM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HCM stock methods without spending real money on the virtual paper trading platform.